Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Oligonucleotide Synthesis ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
Oligonucleotide therapeutics are becoming increasingly popular, with scientists developing treatments for rare diseases, cancer, and respiratory disorders. To ensure their quality, researchers must ...
MyChesCo on MSN14d
Rockland Immunochemicals Advances Oligonucleotide Therapeutics with Novel Bioanalytical TechnologyRockland Immunochemicals, Inc., in collaboration with researchers from the Nucleic Acid Therapeutics Accelerator (NATA) in the United Kingdom, has co-authored a groundbreaking peer-reviewed article ...
A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
It is important to stress that the oligonucleotide probes are designed using the same set of composition rules regardless of the organism or set of RNAs interrogated. This consistency of design ...
Delray Beach, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, reaching US$2.51 billion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback